Compare GHG & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
Current Price
Current Price
| Metric | GHG | VTVT |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.9M | 104.9M |
| IPO Year | 2017 | 2015 |
| Metric | GHG | VTVT |
|---|---|---|
| Price | $1.06 | $21.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $56.00 |
| AVG Volume (30 Days) | ★ 44.9K | 14.2K |
| Earning Date | 12-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $56.17 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.91 | $20.56 |
| 52 Week High | $1.99 | $44.00 |
| Indicator | GHG | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 22.64 |
| Support Level | $0.92 | N/A |
| Resistance Level | $1.13 | $34.65 |
| Average True Range (ATR) | 0.07 | 1.40 |
| MACD | 0.01 | -0.34 |
| Stochastic Oscillator | 78.94 | 4.59 |
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The Group reports its financial results in two operating segments: Hotel Business, which consists of leased-and-operated hotels and franchised-and-managed hotels operating under the hotel related brand, and Restaurant Business, which consists of leased-and-operated restaurants and franchised-and-managed restaurants operating under the brands of Da Niang and Bellagio. It derives maximum revenue from Hotel Business segment. It operates solely in China and generates all its revenue from China itself.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.